Portfolio companies news

27 June 2016

Tobira’s Cenicriviroc Reduces Inflammation and Fibrosis in Animal Models of Chronic Liver and Kidney Disease Including NASH

Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from multiple animal models showed that cenicriviroc (CVC), a potent inhibitor of two chemokine receptors, displayed potent anti-inflammatory and anti-fibrotic activity in multiple organs including liver and kidney.

24 June 2016

Epic Sciences Introduces Sensitive HRD Liquid Biopsy Test for PARP Inhibitor Clinical Trials

Epic Sciences unveiled a liquid biopsy test that more sensitively detects cancers susceptible to PARP inhibitors by targeting homologous recombination deficiency (HRD) in individual circulating tumor cells (CTCs). The new test has already been incorporated into numerous clinical studies of HRD-targeted therapeutics in multiple cancer types.

22 June 2016

Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV

Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, tMarinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that it has dosed the first subject in its Phase 1 clinical trial of ganaxolone IV, an intravenous (IV) formulation of Marinus' CNS-selective GABA_A modulator, for the treatment of status epilepticus (SE). 

16 June 2016

Tobira's Cenicriviroc Shown to Reduce Liver Injury in Independent Research Published in the Journal Hepatology

Tobira Therapeutics, Inc.  (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel treatments for liver and inflammatory diseases, today announced that data from a liver injury model showed that cenicriviroc, a potent inhibitor of two chemokine receptors, attenuates liver inflammation and damage. The results from this study have been published in the journal Heptalogy.

09 June 2016

China Medical Equipment & Technical Service Co. (Meheco) Named the Exclusive Partner for Miramar Labs’ miraDry® Distribution in China

Miramar Labs, Inc., a global aesthetic company announced today that it has entered into an exclusive distribution agreement with Meheco, a state-holding company listed on the Shanghai Stock Exchange. Miramar Labs received the China Food and Drug Administration (CFDA) initial approval in May 2015 for the marketing and sale of miraDry® system in the People’s Republic of China and full approval to distribute its product in April 2016. 

08 June 2016

Miramar Labs, Inc. Completes Alternative Public Offering, Raises $9.0 Million

Miramar Labs, Inc., announced today its successful completion of a reverse merger with Miramar Technologies, Inc., the manufacturers of the miraDry® system which delivers microwave energy to non-invasively destroy sweat and odor glands in the underarm.  The combined entity will trade on the OTC Markets solely focusing on the business of Miramar and has applied for the ticker symbol “MIRA”.

04 June 2016

Presence of AR-V7 in Circulating Tumor Cells Validated as Predictive Biomarker for Advanced Prostate Cancer Treatment by Memorial Sloan Kettering and Epic Sciences

Detecting AR-V7 positive tumor cells circulating in the blood of an advanced prostate cancer patient predicts that he will not only fail the commonly-prescribed androgen receptor signaling inhibitors (ARSI), abiraterone and enzalutamide, but that he will survive significantly longer if treated with a taxane based chemotherapy regimen.

02 June 2016

O’Neill anti-microbial resistance report highlights the necessity for the Atlas io® test platform for infectious diseases

Atlas Genetics Ltd (“Atlas Genetics” or the “Company”), the STI Point-Of-Care (POC) molecular diagnostics company, today notes the major issue of antibiotic resistance for Sexually Transmitted Infections (STIs), as highlighted in the UK Government commissioned anti-microbial resistance report, chaired by Jim O’Neill – ‘Tackling Drug-Resistant Infections Globally’ and recently referenced on the BBC program Newsnight. The O’Neill report recommends that in high income countries health system leaders should ‘support the uptake and use of rapid point-of care diagnostics in primary and secondary care.

01 June 2016

Clearside Biomedical, Inc. Announces Pricing of Initial Public Offering

Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced the pricing of its initial public offering of 7,200,000 shares of its common stock at a public offering price of  $7.00  per share.  

16 May 2016

Syndax Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update Following IPO

Syndax Pharmaceuticals (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat in multiple cancer indications, today reported its financial results for the first quarter ended March 31, 2016, and provided a pipeline update and review of upcoming milestones.  As of March 31, 2016, Syndax had $133.7 million in cash, cash equivalents and short-term investments.